Sinusitis (Ear Nose Throat Disorders) Drugs Pipeline Landscape Report 2021 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Sep 13, 2021--
The “Sinusitis (Ear Nose Throat Disorders) - Drugs In Development, 2021” report has been added to ResearchAndMarkets.com’s offering.
Sinusitis - Drugs In Development, 2021, provides an overview of the Sinusitis (Ear Nose Throat Disorders) pipeline landscape.
Sinusitis - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Sinusitis (Ear Nose Throat Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Sinusitis (Ear Nose Throat Disorders) pipeline guide also reviews of key players involved in therapeutic development for Sinusitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 4, 5, 5, 1, 11, 2 and 1 respectively.
Sinusitis (Ear Nose Throat Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Sinusitis (Ear Nose Throat Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Sinusitis (Ear Nose Throat Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Topics Covered:
- Amgen Inc
- AnaptysBio Inc
- Aodh Lifesciences Pvt Ltd
- Argenx SE
- Armata Pharmaceuticals
- ConMed Biosciences Inc
- Furen Pharmaceutical Group Co Ltd
- GeneOne Life Science Inc
- Genrix (Shanghai) Biopharmaceutical Co Ltd
- GlaxoSmithKline Plc
- GlycoMira Therapeutics Inc
- IVIEW Therapeutics Inc
- Kyowa Kirin Co Ltd
- Lyra Therapeutics Inc
- Maxwell Biosciences Inc
For more information about this report visit https://www.researchandmarkets.com/r/4f109c
View source version on businesswire.com:https://www.businesswire.com/news/home/20210913005668/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2021.
PUB: 09/13/2021 11:43 AM/DISC: 09/13/2021 11:43 AM